Immunosuppressive treatment and progression of histologic lesions in kidney allografts

Kidney International

Volumn 68, Issue SUPPL. 99, 2005, Pages

  Morales, Jose M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Immunosuppresive treatment; Kidney transplantation; Progression of chronic kidney disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; CYCLOSPORIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; TACROLIMUS;

CHRONIC ALLOGRAFT NEPHROPATHY; CONFERENCE PAPER; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; ALLOTRANSPLANTATION; ANIMAL; GLOMERULUS FILTRATION RATE; KIDNEY; KIDNEY DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ANIMALS; CYCLOSPORINE; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RISK FACTORS; SIROLIMUS; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33748301936     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09923.x     Document Type: Conference Paper

References (53)

1. WOLFE RA, ASHBY VB, MILFORD EL, et al: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341:1725-1730, 1999
2. HALLORAN PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med 351:2715-2729, 2004
3. MEIER-KRIESCHE H-U, SCHOLD JD, KAPLAN B: Long-term renal allograft survival: Have made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 4:1289-1295, 2004
4. SERON D, ARIAS M, CAMPISTOL JM, MORALES JM FOR THE SPANISH CHRONIC ALLOGRAFT NEPHROPATHY STUDY GROUP: Transplantation 76:1588-1594, 2003
5. PASCUAL M, THERUVATH T, KAWAI T, et al: Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 346:580-590, 2002
6. MONACO AP, BURKE JF, JR., FERGUSON RM, et al: Current thinking on chronic renal allograft rejection: Issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Kidney Dis 33:150-160, 1999
7. NANKIWELL BJ, BORROWS RJ, FUNG CL S, et al: The natural history of chronic allograft nephropathy. N Engl J Med 394:2326-2333, 2003
8. SOLEZ K, VINCENTI F, FILO RS: Histopathologic findings from 2-year protocols biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK 506 Kidney Transplant Study Group. Transplantation 66:1736-1740, 1988
9. NANKIWELL BJ, BORROWS RJ, FUNG CL-S, et al: Natural history, risk factors and impact of subclinical rejection in kidney transplantation. Transplantation 78:242-249, 2004
10. NANKIWELL BJ, BORROWS RJ, FUNG C S-L, et al: Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 78:434-441, 2004
11. MORESO F, SERON D, CARRERA M, et al: Baseline immunosuppression is associated with histological findings in early protocol biopsies. Transplantation 78:1064-1068, 2004
12. JUREWICZ WA: Tacrolimus versus cyclosporin immunosuppression: Long-term outcome in renal transplantation. Nephrol Dial Transplant 18(Suppl 1):i7-ii11, 2003
13. MURPHY GJ, WALLER JR, SANDORF RS, et al: Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis. Br J Surg 90:680-686, 2003
14. BABOOLAL K, JONES GA, JANEZIC A, et al: Molecular and structural consequences of early renal allograft injury. Kidney Int 61:686-696, 2002
15. BAKKER RC, HOLLANDER AA, MALLAT MJ, et al: Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 64:1027-1034, 2003
16. PLATZ DP, SOLLINGER HW, HULLET DA, et al: RS-61443, a new, potent immunosuppressive agent. Transplantation 51:27-31, 1991
17. EUROPEAN MYCOPHENOLATE MOFETIL COOPERATIVE STUDY GROUP: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345:1321-1325, 1995
18. SQUIFFLET JP, BACKMAN L, CLAESSON K, et al: Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaver renal transplant recipients. Transplantation 72:63-69, 2001
19. SHAPIRO R, YOUNG JB, MILFORD EL, et al: Immunosuppression: Evolution in practice and trends, 1993-2003. Am J Transplant 5:874-886, 2004
20. OJO AO, MEIER-KRIESCHE H-U, HANSON JA, et al: Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69:2405-2409, 2000
21. MATHEW TH: A blinded, long-term, randomized multicentre studies of mycophenolate mofetil in cadaveric renal transplantation: Results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 65:1450-1454, 1998
22. GONZALEZ MOLINA M, SERON D, GARCIA DEL MORAL R, et al: Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. Transplantation 77:215-220, 2004
23. DUDLEY C, POHANKA E, RIAD H, et al: Mycophenolate mofetil substitution for cyclosporine in renal transplant recipients with chronic progressive allograft dysfunction: The "creeping creatinine" study. Transplantation 79:466-475, 2005
24. WEIR MR, WARD MT, BLAHUT SA, et al: Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 59:1567-1573, 2001
25. YILMAZ S, TOMLANOVICH S, MATHEW T, et al: Protocol core needle biopsy and histologic chronic allograft damage index (CADI) as surrogate end-point for long-term graft survival in multicenter studies. J Am Soc Nephrol 14:773-779, 2003
26. SEHGAL SN: Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 31:335-340, 1998
27. MORRIS RE: Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 6:39-87, 1992
28. SHIHAB FS, BENNETT WM, YI H, et al: Combination therapy with sirolimus and mycophenolate mofetil: Effects on the kidney and on transforming grow factor-beta1. Transplantation 77:683-686, 2004
29. IKONEN TS, GUMMERT JF, HAYASE M, et al: Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in nonhuman primates. Transplantation 70:969-975, 2000
30. CASTRO C, CAMPISTOL JM, SANCHO D, et al: Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27Kip1-independent pathway. Atherosclerosis 172:31-38, 2004
31. KAHAN BD, JULIAN BA, PESCOVITZ MD, et al: Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial. Rapamune Study Group. Transplantation 68:1526-1532, 1999
32. KAHAN BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group [see comment]. Lancet 356:194-202, 2000
33. MACDONALD AS, GROUP RGS: A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71:271-280, 2001
34. GROTH CG, BACKMAN L,MORALES JM, et al: Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Transplant Study Group [see comment]. Transplantation 67:1036-1042, 1999
35. KREIS H, CISTERNE JM, LAND W, et al: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.Transplantation 69:1252-1260, 2000
36. MORALES JM, WRAMNER L, KREIS H, et al: Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplantation 2:436-442, 2002
37. FLECHNER SM, GOLDFARB D, MODLIN C, et al: Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74:1070-1076, 2002
38. FLECHNER SM, KURIAN SM, SOLEZ K, et al: De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 4:1776-1785, 2004
39. JOHNSON RW, KREIS H, OBERBAUER R, et al: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure [see comment]. Transplantation 72:777-786, 2001
40. RUIZ JC, CAMPISTOL JM, GRINYO JM, et al: Early cyclosporine A withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 78:1312-1318, 2004
41. STALLONE G, DIPAOLO S, SCHENA A, et al: Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 75:998-1003, 2003
42. OBERBAUER R, KREIS H, JOHNSON RW, et al: Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 76:364-370, 2003
43. KREIS H, OBERBAUER R, CAMPISTOL JM, et al: Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15:809-817, 2004
44. MOTA A, ARIAS M, TASKINEN EI, et al: Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4:953-961, 2004
45. MORALES JM: Cardiovascular risk profile in patients treated with sirolimus. Kidney Int 67(Suppl 93):S69-S73, 2005
46. DIEKMANN F, BUDDE K, OPPENHEIMER F, et al: Predictors of success in conversion from anticalineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4:1869-1875, 2004
47. PEDDI VR, JENSIK S, PESCOVITZ M, et al: An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 19:130-136, 2005
48. DOMINGUEZ-GIL B, ORTIZ M, SIERRA MP, et al: Losartan reduces massive proteinuria in kidney transplant patients: A pilot study. Transplant Proc 34:368-369, 2002.
49. CAMPISTOL JM, INIGO P, JIMENEZ W, et al: Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 56:714-719, 1999
50. NORIS M,AZZOLLINI N, PEZZOTTA A, et al: Combined treatment with mycophenoalte mofetil and an angiotension II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. J Am Soc Nephrol 12:1937-1946, 2001
51. MORALES JM,CAMPISTOL JM,KREIS H, et al: Sirolimus-based therapy with or without cyclosporine: Long-term follow-up in renal transplant patients. Transplant Proc 37:693-696, 2005
52. GRINYO JM, CAMPISTOL JM, PAUL J, et al: Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. Am J Transplant 4:1308-1314, 2004
53. MORALES JM, GRINYO JM, CAMPISTOL JM, et al: Two years of follow-up of a pilot study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. Am J Transplant 5:650, 2005